Welcome to our dedicated page for LIXTE BIOTECHNOLOGY HOLDINGS SEC filings (Ticker: LIXTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LIXTE BIOTECHNOLOGY HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LIXTE BIOTECHNOLOGY HOLDINGS's regulatory disclosures and financial reporting.
Peter Stazzone filed a Form 3 reporting an initial statement of beneficial ownership for Lixte Biotechnology Holdings, Inc. (symbol shown as LIXT) related to an event on 09/01/2025. The filing identifies Mr. Stazzone as an officer with the title Chief Financial Officer and indicates the form was filed by one reporting person. The Form 3 states no securities are beneficially owned by the reporting person. The filing is signed and dated 09/04/2025.
Lixte Biotechnology Holdings, Inc. (LIXTW) Form 3 shows that Felix Lourdes, identified as a Director, filed an initial statement dated 09/01/2025 but reported no securities beneficially owned in the issuer. The signature block is dated 09/04/2025. The filing confirms the director relationship but discloses zero direct or indirect holdings in the company.
Jason David Sawyer, a newly appointed director of Lixte Biotechnology Holdings, Inc. (ticker: LIXT/LIXTW), was granted options to purchase 25,000 shares on 08/15/2025. The options have an exercise price of $3.59 per share, become exercisable immediately for 50% of the grant and vest the remaining 50% in increments—12.5% on 12/31/2025 and 12.5% on the last day of each subsequent calendar quarter—subject to continuous service, and expire on 08/15/2030. The grant was made in connection with Sawyer's appointment to the company’s board. The Form 4 was signed by the reporting person on 08/18/2025.
Michael Andrew Holloway was appointed to the board of Lixte Biotechnology Holdings, Inc. and on August 15, 2025 was granted options to purchase 25,000 shares of common stock at an exercise price of $3.59 per share. The options vest 50% immediately on the effective date and the remaining 50% vests in increments of 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested. The options are exercisable beginning August 15, 2025 and expire on August 15, 2030. The Form 4 was signed by Mr. Holloway on August 18, 2025.
Form 8-K – Item 8.01 (Other Events) filed 11 July 2025 discloses that Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT; warrants LIXTW) issued a 9 July 2025 press release announcing that Nature has published independent research findings that support the scientific rationale underlying the Company’s ongoing Phase II studies in ovarian and colorectal cancers. The Company states that the peer-reviewed article, authored by external physician-scientists, validates the biochemical mechanism targeted by Lixte’s lead compound, thereby reinforcing its clinical development strategy.
There are no financial statements, earnings metrics or transaction details in this filing; the sole purpose is to place the Nature publication on the public record. Management believes the publication may enhance trial enrollment, attract potential partners and improve the Company’s credibility with investors and clinicians, but it does not change the risk profile inherent in early-stage oncology drug development.
- Event date: 9 July 2025 (filed 11 July 2025)
- Affected programs: Ovarian & colorectal cancer trials
- Regulatory status: Unchanged – trials continue; no new FDA submission
- Financial impact: Not quantified; no revenue guidance updated
Overall, the filing is a positive scientific milestone rather than a material financial event, but peer-review validation in a top-tier journal may incrementally strengthen the investment thesis for Lixte’s pipeline.